IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy

Clinical Neurology and Neurosurgery

Volumn 151, Issue , 2016, Pages 31-36

  Li, Hailong ^a   Li, Jiye ^b   Cheng, Gang ^a   Zhang, Jianning ^a   Li, Xuezhen ^c  

^a NAVY GENERAL HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Glioblastoma; IDH mutation; MGMT; Molecular genetics; Pseudoprogression

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE; GLIOBLASTOMA; HEREDITY; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; METHYLATION; MUTATION; OVERALL SURVIVAL; PROMOTER REGION; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; DNA METHYLATION; GENETICS; MIDDLE AGED; OUTCOME ASSESSMENT; PROGNOSIS;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE PROGRESSION; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84992146440     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2016.10.004     Document Type: Article

References (23)

1. [1] Ostrom, Q.T., Gittleman, H., Farah, P., et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 15:Suppl. 2 (2013), ii1–ii56.
2. [2] Stupp, R., Mason, W.P., van den Bent, M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352 (2005), 987–996.
3. [3] Stupp, R., Hegi, M.E., Mason, W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10 (2009), 459–466.
4. [4] Jansen, M., Yip, S., Louis, D.N., Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 9 (2010), 717–726.
5. [5] Brandes, A.A., Franceschi, E., Tosoni, A., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. 26 (2008), 2192–2197.
6. [6] Pouleau, H.B., Sadeghi, N., Baleriaux, D., et al. High levels of cellular proliferation predict pseudoprogression in glioblastoma patients. Int. J. Oncol. 40 (2012), 923–928.
7. [7] Knudsen-Baas, K.M., Moen, G., Fluge, O., et al. Pseudoprogression in high-grade glioma. Acta Neurol. Scand.(Suppl), 2013, 31–37.
8. [8] Topkan, E., Topuk, S., Oymak, E., et al. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Am. J. Clin. Oncol. 35 (2012), 284–289.
9. [9] Sanghera, P., Perry, J., Sahgal, A., et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can. J. Neurol. Sci. 37 (2010), 36–42.
10. [10] Wen, P.Y., Macdonald, D.R., Reardon, D.A., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28 (2010), 1963–1972.
11. [11] Fabi, A., Russillo, M., Metro, G., et al. Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice. Anticancer Res. 29 (2009), 2607–2610.
12. [12] Kang, H.C., Kim, C.Y., Han, J.H., et al. Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53. J. Neurooncol. 102 (2011), 157–162.
13. [13] Motegi, H., Kamoshima, Y., Terasaka, S., et al. IDH1 mutation as a potential novel biomarker for distinguishing pseudoprogression from true progression in patients with glioblastoma treated with temozolomide and radiotherapy. Brain Tumor Pathol. 30 (2013), 67–72.
14. [14] Radbruch, A., Fladt, J., Kickingereder, P., et al. Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. Neuro Oncol., 2014.
15. [15] Ren, X., Cui, X., Lin, S., et al. Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients. PLoS One, 7, 2012, e32764.
16. [16] Bae, S.I., Lee, H.S., Kim, S.H., et al. Inactivation of O6-methylguanine-DNA methyltransferase by promoter CpG island hypermethylation in gastric cancers. Br. J. Cancer 86 (2002), 1888–1892.
17. [17] Ho, M., Yu, D., Davidsion, M.C., et al. Comparison of standard surface chemistries for culturing mesenchymal stem cells prior to neural differentiation. Biomaterials 27 (2006), 4333–4339.
18. [18] Hygino da Cruz, L.C. Jr., Rodriguez, I., Domingues, R.C., et al. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am. J. Neuroradiol. 32 (2011), 1978–1985.
19. [19] Tran, D.K., Jensen, R.L., Treatment-related brain tumor imaging changes: so-called pseudoprogression vs. tumor progression: review and future research opportunities. Surg. Neurol. Int. 4 (2013), S129–S135.
20. [20] Hu, L.S., Eschbacher, J.M., Heiserman, J.E., et al. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro Oncol. 14 (2012), 919–930.
21. [21] Sun, H., Yin, L., Li, S., et al. Prognostic significance of IDH mutation in adult low-grade gliomas: a meta-analysis. J. Neurooncol. 113 (2013), 277–284.
22. [22] Houillier, C., Wang, X., Kaloshi, G., et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75 (2010), 1560–1566.
23. [23] Leu, S., von Felten, S., Frank, S., et al. IDH/MGMT-driven molecular classification of low-grade glioma is a strong predictor for long-term survival. Neuro Oncol. 15 (2013), 469–479.